Icosavax Q2 EPS $(0.59) Beats $(0.60) Estimate
Portfolio Pulse from Benzinga Newsdesk
Icosavax (NASDAQ:ICVX) reported Q2 losses of $(0.59) per share, beating the analyst consensus estimate of $(0.60) by 1.67 percent. However, this represents a 3.51 percent increase in losses compared to the same period last year.
August 14, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Icosavax's Q2 earnings beat estimates but losses increased compared to last year. This mixed result may lead to uncertain market reactions.
Icosavax's earnings beat estimates, which is generally positive for the stock. However, the increase in losses compared to the same period last year may offset this positive impact. Therefore, the short-term impact on the stock price is uncertain.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100